anti recql4 antibody  (Proteintech)

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 immunohistochemistry. Representative microphotographs of RECQL4 immunohistochemistry staining. (A) HGG with high RECQL4 expression (H-score: 180). (B) HGG with intermediate RECQL4 expression (H-score: 80). (C) Angiocentric glioma with low RECQL4 expression (H-score: 10). HGG, adult-type diffuse high-grade glioma.

Article Snippet: Immunohistochemistry (IHC) with anti-RECQL4 antibody (Proteintech 17008-1-AP, 1:50) was utilized on a tissue microarray (TMA) consisting of 21 low-grade gliomas ([LGG]; 17 low-grade circumscribed gliomas [LGCG] and 4 low-grade diffuse gliomas [LGDG] all of which were angiocentric gliomas, AG); 41 adult-type diffuse high-grade gliomas ([HGG], grade 4); and 99 nerve sheath tumors, comprising 67 neurofibromas and 32 malignant peripheral nerve sheath tumors (MPNST).

Techniques: Immunohistochemistry, Staining, Expressing

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 immunohistochemistry in gliomas. (A) RECQL4 immunohistochemical H-scores in low-grade circumscribed glioma (LGCG, n = 42), low-grade diffuse glioma (LGDG, n = 4), and high-grade glioma (HGG, n = 65); expression differed significantly across the groups (Kruskal–Wallis test, χ 2 = 8.78, df = 2, P = 0.012). (B) RECQL4 immunohistochemical H-scores in low-grade circumscribed glioma subtypes, namely subependymal giant-cell astrocytoma (SEGA, n = 2), pilocytic astrocytoma (PA, n = 7), and pleomorphic xanthoastrocytoma (PXA, n = 8). H-scores were similar across groups (Kruskal–Wallis test, χ 2 = 0.003, df = 2, P = 0.999).

Article Snippet: Immunohistochemistry (IHC) with anti-RECQL4 antibody (Proteintech 17008-1-AP, 1:50) was utilized on a tissue microarray (TMA) consisting of 21 low-grade gliomas ([LGG]; 17 low-grade circumscribed gliomas [LGCG] and 4 low-grade diffuse gliomas [LGDG] all of which were angiocentric gliomas, AG); 41 adult-type diffuse high-grade gliomas ([HGG], grade 4); and 99 nerve sheath tumors, comprising 67 neurofibromas and 32 malignant peripheral nerve sheath tumors (MPNST).

Techniques: Immunohistochemistry, Immunohistochemical staining, Expressing

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 immunohistochemistry in nerve sheath tumors. RECQL4 H-scores across cases of neurofibromas ( n = 67), NF1-related malignant peripheral nerve sheath tumors (MPNST, n = 24), and sporadic MPNST ( n = 8). Global comparison performed using Kruskal–Wallis test (χ² = 20.54, df = 2, P = 0.000035).

Article Snippet: Immunohistochemistry (IHC) with anti-RECQL4 antibody (Proteintech 17008-1-AP, 1:50) was utilized on a tissue microarray (TMA) consisting of 21 low-grade gliomas ([LGG]; 17 low-grade circumscribed gliomas [LGCG] and 4 low-grade diffuse gliomas [LGDG] all of which were angiocentric gliomas, AG); 41 adult-type diffuse high-grade gliomas ([HGG], grade 4); and 99 nerve sheath tumors, comprising 67 neurofibromas and 32 malignant peripheral nerve sheath tumors (MPNST).

Techniques: Immunohistochemistry, Comparison

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 knockdown in glioma. Glioma cell line U251 with its RECQL4-knockdowns (RECQL4sh2 and RECQL4sh5) and empty vector control (pLKO.1). Cell numbers measured at multiple time points (upper). Percentage of BrdU-positive cells (lower left). Percentage of apoptotic cells (lower right).

Article Snippet: Immunohistochemistry (IHC) with anti-RECQL4 antibody (Proteintech 17008-1-AP, 1:50) was utilized on a tissue microarray (TMA) consisting of 21 low-grade gliomas ([LGG]; 17 low-grade circumscribed gliomas [LGCG] and 4 low-grade diffuse gliomas [LGDG] all of which were angiocentric gliomas, AG); 41 adult-type diffuse high-grade gliomas ([HGG], grade 4); and 99 nerve sheath tumors, comprising 67 neurofibromas and 32 malignant peripheral nerve sheath tumors (MPNST).

Techniques: Knockdown, Plasmid Preparation, Control

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 knockdown in MPNST. Malignant peripheral nerve sheath tumor cell line NF90-8 with its RECQL4-knockdowns (RECQL4sh2 and RECQL4sh5) and empty vector control (pLKO.1). Cell numbers measured at multiple time points (upper). Percentage of BrdU-positive cells (lower left). Percentage of apoptotic cells (lower right).

Article Snippet: Immunohistochemistry (IHC) with anti-RECQL4 antibody (Proteintech 17008-1-AP, 1:50) was utilized on a tissue microarray (TMA) consisting of 21 low-grade gliomas ([LGG]; 17 low-grade circumscribed gliomas [LGCG] and 4 low-grade diffuse gliomas [LGDG] all of which were angiocentric gliomas, AG); 41 adult-type diffuse high-grade gliomas ([HGG], grade 4); and 99 nerve sheath tumors, comprising 67 neurofibromas and 32 malignant peripheral nerve sheath tumors (MPNST).

Techniques: Knockdown, Plasmid Preparation, Control

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 knockdown in MPNST. Malignant peripheral nerve sheath tumor cell line ST88-14 with its RECQL4-knockouts (RECQL4sh2 and RECQL4sh5) and empty vector control (pLKO.1). Cell numbers measured at multiple time points (upper). Percentage of BrdU-positive cells (lower left). Percentage of apoptotic cells (lower right).

Article Snippet: Immunohistochemistry (IHC) with anti-RECQL4 antibody (Proteintech 17008-1-AP, 1:50) was utilized on a tissue microarray (TMA) consisting of 21 low-grade gliomas ([LGG]; 17 low-grade circumscribed gliomas [LGCG] and 4 low-grade diffuse gliomas [LGDG] all of which were angiocentric gliomas, AG); 41 adult-type diffuse high-grade gliomas ([HGG], grade 4); and 99 nerve sheath tumors, comprising 67 neurofibromas and 32 malignant peripheral nerve sheath tumors (MPNST).

Techniques: Knockdown, Plasmid Preparation, Control

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: ATR inhibition decreases cell growth in tumor cells with RECQL4 loss. Effect of ATR kinase inhibition on cell proliferation of glioma and malignant peripheral nerve sheath tumor (MPNST) cell lines and their RECQL4-knockouts. Glioma U251 cell line survival fraction at different dosages of AZD6738 (Upper left) and VE-821 (Upper right). MPNST NF90-8 cell line survival fraction at different dosages of AZD6738 (Mid left)) and VE-821 (Mid right). MPNST ST88-14 cell line survival fraction at different dosages of AZD6738 (Lower left) and VE-821 (Lower right)).

Article Snippet: Immunohistochemistry (IHC) with anti-RECQL4 antibody (Proteintech 17008-1-AP, 1:50) was utilized on a tissue microarray (TMA) consisting of 21 low-grade gliomas ([LGG]; 17 low-grade circumscribed gliomas [LGCG] and 4 low-grade diffuse gliomas [LGDG] all of which were angiocentric gliomas, AG); 41 adult-type diffuse high-grade gliomas ([HGG], grade 4); and 99 nerve sheath tumors, comprising 67 neurofibromas and 32 malignant peripheral nerve sheath tumors (MPNST).

Techniques: Inhibition

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 immunohistochemistry. Representative microphotographs of RECQL4 immunohistochemistry staining. (A) HGG with high RECQL4 expression (H-score: 180). (B) HGG with intermediate RECQL4 expression (H-score: 80). (C) Angiocentric glioma with low RECQL4 expression (H-score: 10). HGG, adult-type diffuse high-grade glioma.

Article Snippet: The primary antibody utilized for Western blot analysis was RECQL4 (17008-1-AP, 1:2000, Proteintech, Rosemont, IL, USA), the secondary antibodies used was anti-rabbit IgG HRP-linked (#7074, 1:5000, Cell Signaling Technology).

Techniques: Immunohistochemistry, Staining, Expressing

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 immunohistochemistry in gliomas. (A) RECQL4 immunohistochemical H-scores in low-grade circumscribed glioma (LGCG, n = 42), low-grade diffuse glioma (LGDG, n = 4), and high-grade glioma (HGG, n = 65); expression differed significantly across the groups (Kruskal–Wallis test, χ 2 = 8.78, df = 2, P = 0.012). (B) RECQL4 immunohistochemical H-scores in low-grade circumscribed glioma subtypes, namely subependymal giant-cell astrocytoma (SEGA, n = 2), pilocytic astrocytoma (PA, n = 7), and pleomorphic xanthoastrocytoma (PXA, n = 8). H-scores were similar across groups (Kruskal–Wallis test, χ 2 = 0.003, df = 2, P = 0.999).

Article Snippet: The primary antibody utilized for Western blot analysis was RECQL4 (17008-1-AP, 1:2000, Proteintech, Rosemont, IL, USA), the secondary antibodies used was anti-rabbit IgG HRP-linked (#7074, 1:5000, Cell Signaling Technology).

Techniques: Immunohistochemistry, Immunohistochemical staining, Expressing

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 immunohistochemistry in nerve sheath tumors. RECQL4 H-scores across cases of neurofibromas ( n = 67), NF1-related malignant peripheral nerve sheath tumors (MPNST, n = 24), and sporadic MPNST ( n = 8). Global comparison performed using Kruskal–Wallis test (χ² = 20.54, df = 2, P = 0.000035).

Article Snippet: The primary antibody utilized for Western blot analysis was RECQL4 (17008-1-AP, 1:2000, Proteintech, Rosemont, IL, USA), the secondary antibodies used was anti-rabbit IgG HRP-linked (#7074, 1:5000, Cell Signaling Technology).

Techniques: Immunohistochemistry, Comparison

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 knockdown in glioma. Glioma cell line U251 with its RECQL4-knockdowns (RECQL4sh2 and RECQL4sh5) and empty vector control (pLKO.1). Cell numbers measured at multiple time points (upper). Percentage of BrdU-positive cells (lower left). Percentage of apoptotic cells (lower right).

Article Snippet: The primary antibody utilized for Western blot analysis was RECQL4 (17008-1-AP, 1:2000, Proteintech, Rosemont, IL, USA), the secondary antibodies used was anti-rabbit IgG HRP-linked (#7074, 1:5000, Cell Signaling Technology).

Techniques: Knockdown, Plasmid Preparation, Control

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 knockdown in MPNST. Malignant peripheral nerve sheath tumor cell line NF90-8 with its RECQL4-knockdowns (RECQL4sh2 and RECQL4sh5) and empty vector control (pLKO.1). Cell numbers measured at multiple time points (upper). Percentage of BrdU-positive cells (lower left). Percentage of apoptotic cells (lower right).

Article Snippet: The primary antibody utilized for Western blot analysis was RECQL4 (17008-1-AP, 1:2000, Proteintech, Rosemont, IL, USA), the secondary antibodies used was anti-rabbit IgG HRP-linked (#7074, 1:5000, Cell Signaling Technology).

Techniques: Knockdown, Plasmid Preparation, Control

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: RECQL4 knockdown in MPNST. Malignant peripheral nerve sheath tumor cell line ST88-14 with its RECQL4-knockouts (RECQL4sh2 and RECQL4sh5) and empty vector control (pLKO.1). Cell numbers measured at multiple time points (upper). Percentage of BrdU-positive cells (lower left). Percentage of apoptotic cells (lower right).

Article Snippet: The primary antibody utilized for Western blot analysis was RECQL4 (17008-1-AP, 1:2000, Proteintech, Rosemont, IL, USA), the secondary antibodies used was anti-rabbit IgG HRP-linked (#7074, 1:5000, Cell Signaling Technology).

Techniques: Knockdown, Plasmid Preparation, Control

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications

doi: 10.1093/jnen/nlaf129

Figure Lengend Snippet: ATR inhibition decreases cell growth in tumor cells with RECQL4 loss. Effect of ATR kinase inhibition on cell proliferation of glioma and malignant peripheral nerve sheath tumor (MPNST) cell lines and their RECQL4-knockouts. Glioma U251 cell line survival fraction at different dosages of AZD6738 (Upper left) and VE-821 (Upper right). MPNST NF90-8 cell line survival fraction at different dosages of AZD6738 (Mid left)) and VE-821 (Mid right). MPNST ST88-14 cell line survival fraction at different dosages of AZD6738 (Lower left) and VE-821 (Lower right)).

Article Snippet: The primary antibody utilized for Western blot analysis was RECQL4 (17008-1-AP, 1:2000, Proteintech, Rosemont, IL, USA), the secondary antibodies used was anti-rabbit IgG HRP-linked (#7074, 1:5000, Cell Signaling Technology).

Techniques: Inhibition

Journal: Experimental & molecular medicine

Article Title: RECQL4 requires PARP1 for recruitment to DNA damage, and PARG dePARylation facilitates its associated role in end joining.

doi: 10.1038/s12276-024-01383-z

Figure Lengend Snippet: Fig. 1 RECQL4-catalyzed strand annealing activity is stimulated by non-PARylated PARP1. a, b, The strand annealing activity of RECQL4 (10 nM) examined in the presence of increasing concentrations (0, 1, 5, 10, 20, 40 and 80 nM) of non-PARylated PARP1 (PARP1) (a) or PAR (b) with radiolabeled ssDNA 80 mer DNA and its complimentary single-stranded DNA. c, Graph showing the quantitative results of a and b. d, e, BLM (10 nM) strand annealing activity measured in the presence of increasing concentrations (0, 1, 5, 10, 20, 40 and 80 nM) of non- PARylated PARP1 (PARP1) (d) or PAR (e) with radiolabeled ssDNA 80 mer DNA and its complimentary single-stranded DNA. f, Graph showing the quantification results of d and e. g, h, Helicase activity of RECQL4 (100 nM) measured in the presence of increasing concentrations (1, 5, 10, 50 and 100 nM) of non-PARylated PARP1 (g) or PAR (h) with radiolabeled duplex fork DNA. i, A graph showing the quantitative results of g and h. j, k, BLM helicase activity (0.5 nM) was measured in the presence of increasing concentrations (1, 5, 10, 50 and 100 nM) of non-PARylated PARP1 (j) or PAR (k) with radiolabeled duplex fork DNA. l, Graph showing the quantification results of j and k. PARP1 and PAR alone have no helicase activity and Δ represents the denatured substrate control. All experiments were repeated at least three times and the error bars represent the s.e.m.

Article Snippet: The antibodies used were RECQL4 (made in house)11,40, BLM (NB100-214 Novus Biologicals), GFP (sc-8334, Santa Cruz), DNA ligase I (sc-20222, Santa Cruz), DNA ligase III (1F3, GeneTex), PARP1 (9542L, Cell Signaling), PAR (4336-BPC-100, Trevigen), XRCC1 (GTX23133, GeneTex), FLAG (F1804, Sigma), V5 (R960-CUS, Invitrogen) and Tubulin (sc5286, Santa Cruz).

Techniques: Activity Assay, Control

Journal: Experimental & molecular medicine

Article Title: RECQL4 requires PARP1 for recruitment to DNA damage, and PARG dePARylation facilitates its associated role in end joining.

doi: 10.1038/s12276-024-01383-z

Figure Lengend Snippet: Fig. 4 Identification of the PARP1 domains required for interaction with RECQL4. a, An illustration of V5-tagged full-length PARP1 and fragments used for binding assays. The numbers denote amino acid (aa) residues. The results from b are scored in the right column as RECQL4 binding. b, Cell extracts from HEK293T cells expressing V5-tagged full-length or fragments of PARP1 with or without Flag–RECQL4 were immunoprecipitated with an anti-FLAG antibody, followed by immuno blotting (IB) with an anti-V5 antibody. c, An illustration of Flag-tagged full-length RECQL4 and fragments used for binding assays. The numbers denote amino acid residues. Sld2-like domain and HD. The results from d are scored with + in the right column as PARP1 binding. d, After 10 Gy of IR DNA damage, extracts from HEK293T cells expressing Flag- tagged full-length or fragments of RECQL4 with V5-tagged PARP1 were immunoprecipitated with an anti-V5 antibody, followed by western blotting with anti-Flag and anti-V5 antibodies.

Article Snippet: The antibodies used were RECQL4 (made in house)11,40, BLM (NB100-214 Novus Biologicals), GFP (sc-8334, Santa Cruz), DNA ligase I (sc-20222, Santa Cruz), DNA ligase III (1F3, GeneTex), PARP1 (9542L, Cell Signaling), PAR (4336-BPC-100, Trevigen), XRCC1 (GTX23133, GeneTex), FLAG (F1804, Sigma), V5 (R960-CUS, Invitrogen) and Tubulin (sc5286, Santa Cruz).

Techniques: Binding Assay, Expressing, Immunoprecipitation, Western Blot

Journal: Experimental & molecular medicine

Article Title: RECQL4 requires PARP1 for recruitment to DNA damage, and PARG dePARylation facilitates its associated role in end joining.

doi: 10.1038/s12276-024-01383-z

Figure Lengend Snippet: Fig. 7 A model for the mechanism by which PARP1 regulates RECQL4 recruitment to DSB sites. After DNA damage, RECQL4 interacts with PARP1 and undergoes PARylation, which is essential for its recruitment at DSB sites to promote the alt-NHEJ pathway. PARP1 KO and PARPi treatment results in no PARylation of RECQL4 after DNA damage and hampers its recruitment to DNA damage sites. Furthermore, PARG removes PARylation repressive marks from PARP1 and RECQL4 so that they can perform their role in alt-NHEJ DNA repair. (The model was generated using BioRender).

Article Snippet: The antibodies used were RECQL4 (made in house)11,40, BLM (NB100-214 Novus Biologicals), GFP (sc-8334, Santa Cruz), DNA ligase I (sc-20222, Santa Cruz), DNA ligase III (1F3, GeneTex), PARP1 (9542L, Cell Signaling), PAR (4336-BPC-100, Trevigen), XRCC1 (GTX23133, GeneTex), FLAG (F1804, Sigma), V5 (R960-CUS, Invitrogen) and Tubulin (sc5286, Santa Cruz).

Techniques: Generated